c-Myb supports erythropoiesis through the transactivation of KLF1 and LMO2 expression

Department of Biomedical Sciences, Biological Chemistry Section, University of Modena and Reggio Emilia, Modena, Italy.
Blood (Impact Factor: 10.45). 11/2010; 116(22):e99-110. DOI: 10.1182/blood-2009-08-238311
Source: PubMed


The c-myb transcription factor is highly expressed in immature hematopoietic cells and down-regulated during differentiation. To define its role during the hematopoietic lineage commitment, we silenced c-myb in human CD34(+) hematopoietic stem/progenitor cells. Noteworthy, c-myb silencing increased the commitment capacity toward the macrophage and megakaryocyte lineages, whereas erythroid differentiation was impaired, as demonstrated by clonogenic assay, morphologic and immunophenotypic data. Gene expression profiling and computational analysis of promoter regions of genes modulated in c-myb-silenced CD34(+) cells identified the transcription factors Kruppel-Like Factor 1 (KLF1) and LIM Domain Only 2 (LMO2) as putative targets, which can account for c-myb knockdown effects. Indeed, chromatin immunoprecipitation and luciferase reporter assay demonstrated that c-myb binds to KLF1 and LMO2 promoters and transactivates their expression. Consistently, the retroviral vector-mediated overexpression of either KLF1 or LMO2 partially rescued the defect in erythropoiesis caused by c-myb silencing, whereas only KLF1 was also able to repress the megakaryocyte differentiation enhanced in Myb-silenced CD34(+) cells. Our data collectively demonstrate that c-myb plays a pivotal role in human primary hematopoietic stem/progenitor cells lineage commitment, by enhancing erythropoiesis at the expense of megakaryocyte diffentiation. Indeed, we identified KLF1 and LMO2 transactivation as the molecular mechanism underlying Myb-driven erythroid versus megakaryocyte cell fate decision.

Full-text preview

Available from:
    • "c-Myb is an essential transcription factor for normal erythropoiesis, and activates GATA-1, c-kit, LMO2 and KLF1 (Melotti and Calabretta, 1996; Bianchi et al., 2010). After activation by c- Myb and derepression of ALK4 receptor that is necessary to stimulate β-globin synthesis, KLF1 activates BCL11A transcription factor and increases β-globin synthesis, inhibits g-globin synthesis and increases Hb A synthesis (Bianchi et al., 2010; Zhou et al., 2010). c-Myb-activated GATA-1 activates the expression of miR-451 and miR-144 by interfering with LMO2 (Dore et al., 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: MicroRNAs (miRNAs) are 19-24 nucleotide non-coding ribonucleic acids binding DNA or RNA and controlling gene expression via mRNA degradation or its transcription inhibition. Erythropoies is a multi step differentiation process of erythroid progenitors to nucleate red blood cells. Maturation, proliferation and differentiation of red blood cells is affected by erythroid factors, signaling pathways in niche of hematopoietic cells, transcription factors as well as miRNAs. Expression of different types of miRNAs during erythroid development provides a background for the study of these molecules to control erythroid differentiation and maturation as well as their use as diagnostic and prognostic markers to treat erythroid disorders like thalassemia, sickle cell disease and erythrocyte enzyme deficiencies. In this paper, with reference to biosynthesis of miRNAs, their function in normal and anemic erythropoiesis has been investigated. The target molecule of each of these miRNAs has been cited in an attempt to elucidate their role in erythropoiesis. © 2015, Higher Education Press and Springer-Verlag Berlin Heidelberg.
    07/2015; 10(4). DOI:10.1007/s11515-015-1365-z
  • Source
    • "The expression of transcription factors c-Myb, GATA-2, and Fli1 is also appeared to be modified by THAP11 overexpression. A previous study reported that c-Myb silencing in human CD34+ hematopoietic stem/progenitor cells increased commitment capacity toward the macrophage and megakaryocyte lineages but impaired erythroid differentiation [21] suggesting that c-Myb regulates erythroid differentiation in a positive manner. GATA-2 is a key transcription factor in controlling cell fate outcome within the stem and early progenitor cell compartments and plays an important role in hematopoietic commitment [22] [23]. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Hematopoiesis is a complex process regulated by sets of transcription factors in a stage-specific and context-dependent manner. THAP11 is a transcription factor involved in cell growth, ES cell pluripotency, and embryogenesis. Here we showed that THAP11 was down-regulated during erythroid differentiation but up-regulated during megakaryocytic differentiation of cord blood CD34+ cells. Overexpression of THAP11 in K562 cells inhibited the erythroid differentiation induced by hemin with decreased numbers of benzidine-positive cells and decreased mRNA levels of α-globin (HBA) and glycophorin A (GPA), and knockdown of THAP11 enhanced the erythroid differentiation. Conversely, THAP11 overexpression accelerated the megakaryocytic differentiation induced by phorbol myristate acetate (PMA) with increased percentage of CD41+ cells, increased numbers of 4N cells, and elevated CD61 mRNA levels, and THAP11 knockdown attenuated the megakaryocytic differentiation. The expression levels of transcription factors such as c-Myc, c-Myb, GATA-2, and Fli1 were changed by THAP11 overexpression. In this way, our results suggested that THAP11 reversibly regulated erythroid and megakaryocytic differentiation.
    PLoS ONE 03/2014; 9(3):e91557. DOI:10.1371/journal.pone.0091557 · 3.23 Impact Factor
  • Source
    • "Our data show that overexpression of MYB, without its known miR-150 binding sites in the 3’ UTR, decreases CD11b expression. These results are consistent with published reports that MYB expression blocks terminal differentiation and MYB silencing enhances monocyte/macrophage differentiation [32,33]. There are several possible explanations for the observation of only a partial reversal of differentiation. "
    [Show abstract] [Hide abstract]
    ABSTRACT: In acute myeloid leukemia (AML) and blast crisis (BC) chronic myeloid leukemia (CML) normal differentiation is impaired. Differentiation of immature stem/progenitor cells is critical for normal blood cell function. MicroRNAs (miRNAs or miRs) are small non-coding RNAs that interfere with gene expression by degrading messenger RNAs (mRNAs) or blocking protein translation. Aberrant miRNA expression is a feature of leukemia and miRNAs also play a significant role in normal hematopoiesis and differentiation. We have identified miRNAs differentially expressed in AML and BC CML and identified a new role for miR-150 in myeloid differentiation. Expression of miR-150 is low or absent in BC CML and AML patient samples and cell lines. We have found that expression of miR-150 in AML cell lines, CD34+ progenitor cells from healthy individuals, and primary BC CML and AML patient samples at levels similar to miR-150 expression in normal bone marrow promotes myeloid differentiation of these cells. MYB is a direct target of miR-150, and we have identified that the observed phenotype is partially mediated by MYB. In AML cell lines, differentiation of miR-150 expressing cells occurs independently of retinoic acid receptor α (RARA) signaling. High-throughput gene expression profiling (GEP) studies of the AML cell lines HL60, PL21, and THP-1 suggest that activation of CEPBA, CEBPE, and cytokines associated with myeloid differentiation in miR-150 expressing cells as compared to control cells contributes to myeloid differentiation. These data suggest that miR-150 promotes myeloid differentiation, a previously uncharacterized role for this miRNA, and that absent or low miR-150 expression contributes to blocked myeloid differentiation in acute leukemia cells.
    PLoS ONE 09/2013; 8(9):e75815. DOI:10.1371/journal.pone.0075815 · 3.23 Impact Factor
Show more